The following data were reported at the at the American Academy of Neurology annual meeting in Toronto:

• Avid Radiopharmaceuticals Inc., of Philadelphia, presented interim data from its florbetapir "Image-to-Autopsy" Phase III study. The interim data showed that florbetapir PET imaging results in patients correlated with the levels of beta-amyloid pathology later found in their brains at autopsy. The data suggested that florbetapir imaging may offer an opportunity to detect amyloid plaques in-life.

• Opexa Therapeutics Inc., of The Woodlands, Texas, presented efficacy data in showing promising efficacy and safety results in patients treated with Tovaxin, the company's lead therapy for multiple sclerosis. The presentation highlighted previously communicated efficacy data as well as new immunology data that appear to link Tovaxin's mechanism of action with observed clinical benefits. Shares in Opexa (NASDAQ:OPXAW) were down 4 cents, closing at $1.22 Thursday.